



Commissioner for Patents  
Washington, DC 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/899,634	07/05/2001	Thomas Buhler	4-31499A

001095  
 THOMAS HOXIE  
 NOVARTIS CORPORATION  
 PATENT AND TRADEMARK DEPT  
 564 MORRIS AVENUE  
 SUMMIT, NJ 079011027

**CONFIRMATION NO. 5159**  
**WITHDRAWAL NOTICE**



\*OC000000008884874\*

Date Mailed: 10/07/2002

**WITHDRAWAL OF PREVIOUSLY SENT NOTICE**

The Notice mailed on 12/18/2001 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. We apologize for any inconvenience this caused.

*A copy of this notice **MUST** be returned with the reply.*

---

Customer Service Center  
 Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY



Commissioner for Patents  
Washington, DC 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/899,634	07/05/2001	Thomas Buhler	4-31499A

001095  
 THOMAS HOXIE  
 NOVARTIS CORPORATION  
 PATENT AND TRADEMARK DEPT  
 564 MORRIS AVENUE  
 SUMMIT, NJ 079011027

**CONFIRMATION NO. 5159**  
**FORMALITIES LETTER**



\*OC000000008916929\*

Date Mailed: 10/07/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*